^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    2d
    The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2d
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (clinicaltrials.gov)
    P2, N=39, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    AiTan (rivoceranib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    BRICES: QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    3d
    QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial (clinicaltrials.gov)
    P2, N=50, Recruiting, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
    New P2 trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    3d
    QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
    New P2 trial
    |
    cisplatin • carboplatin • Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)
    3d
    Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • Qibeian (iparomlimab/tuvonralimab)
    7d
    Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review. (PubMed, BMC Cardiovasc Disord)
    We report the first documented case of myocarditis linked to the novel bifunctional PD-1/CTLA-4 combination, Iparomlimab and Tuvonralimab. This case highlights that structural drug optimizations do not preclude severe cardiotoxicity. In resource-limited settings lacking advanced imaging, serial high-sensitivity troponin monitoring served as the cornerstone for early detection and guiding management. This experience confirms that favorable outcomes are achievable through vigilant biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • ICOS (Inducible T Cell Costimulator)
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • Inlyta (axitinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    10d
    A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    10d
    Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=290, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    cisplatin • carboplatin • Qibeian (iparomlimab/tuvonralimab)
    14d
    TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Fudan University
    New trial • IO biomarker
    |
    Qibeian (iparomlimab/tuvonralimab)
    15d
    Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)